Natera Inc (NASDAQ:NTRA) insider Matthew Rabinowitz sold 614 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $20.25, for a total value of $12,433.50. Following the completion of the sale, the insider now owns 1,284,408 shares of the company’s stock, valued at approximately $26,009,262. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Matthew Rabinowitz also recently made the following trade(s):
- On Monday, March 11th, Matthew Rabinowitz sold 5,672 shares of Natera stock. The shares were sold at an average price of $16.00, for a total value of $90,752.00.
NTRA opened at $20.63 on Wednesday. The company has a debt-to-equity ratio of 2.28, a quick ratio of 1.99 and a current ratio of 2.11. Natera Inc has a 52-week low of $10.64 and a 52-week high of $29.62. The company has a market cap of $1.28 billion, a PE ratio of -9.60 and a beta of 1.89.
Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, March 12th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.51). Natera had a negative return on equity of 790.13% and a negative net margin of 49.72%. The firm had revenue of $67.00 million for the quarter, compared to analysts’ expectations of $62.87 million. As a group, equities analysts anticipate that Natera Inc will post -2.24 EPS for the current year.
Several institutional investors and hedge funds have recently bought and sold shares of NTRA. Great West Life Assurance Co. Can increased its stake in shares of Natera by 136.8% during the fourth quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock valued at $80,000 after buying an additional 3,420 shares during the period. Legal & General Group Plc increased its stake in shares of Natera by 14.5% during the fourth quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock valued at $81,000 after buying an additional 736 shares during the period. Pacer Advisors Inc. purchased a new position in shares of Natera during the third quarter valued at approximately $106,000. Point72 Hong Kong Ltd purchased a new position in shares of Natera during the third quarter valued at approximately $119,000. Finally, State Board of Administration of Florida Retirement System increased its stake in shares of Natera by 6.7% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 11,485 shares of the medical research company’s stock valued at $160,000 after buying an additional 717 shares during the period. 87.76% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have weighed in on NTRA shares. ValuEngine downgraded Natera from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 9th. Canaccord Genuity reiterated a “buy” rating and issued a $25.00 price objective on shares of Natera in a research report on Monday, March 11th. BidaskClub upgraded Natera from a “strong sell” rating to a “sell” rating in a research report on Wednesday, February 20th. Finally, Zacks Investment Research downgraded Natera from a “hold” rating to a “sell” rating in a research report on Wednesday, March 27th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $27.75.
COPYRIGHT VIOLATION NOTICE: “Insider Selling: Natera Inc (NTRA) Insider Sells 614 Shares of Stock” was originally reported by Stock Observer and is the property of of Stock Observer. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thestockobserver.com/2019/04/17/insider-selling-natera-inc-ntra-insider-sells-614-shares-of-stock.html.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Further Reading: Is it Safe to Invest in Commodities?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.